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The hemodialysis population is characterized by a high
prevalence of ‘asymptomatic’ coronary artery disease (CAD),
which should be interpreted differently from asymptomatic
disease in the general population. A hemodynamically
significant stenosis may not become clinically apparent
owing to impaired exercise tolerance and autonomic
neuropathy. The continuous presence of silent ischemia may
cause heart failure, arrhythmias, and sudden death. Whether
revascularization of an asymptomatic dialysis patient
improves outcome remains a moot point, although several
observational studies and one small RCT suggest a benefit.
It can therefore be defended to screen asymptomatic dialysis
patients for CAD. A number of noninvasive screening tests
are available, but none has proved equally practical and
reliable in the dialysis population as in the general
population. Myocardial perfusion scintigraphy (MPS) before
and after a pharmacological stress such as dipyridamole can
reveal both ischemia and myocardial scarring. When
compared with coronary angiography, low sensitivities
were reported and attributed to impaired vasodilation to
dipyridamole in dialysis patients. A more likely explanation
is that not every anatomical stenosis will lead to impaired
coronary blood flow on MPS. Numerous studies have shown
an incremental prognostic value of dipyridamole-MPS over
clinical data for prediction of adverse cardiac events, in some
studies even over coronary angiography. Pending the
availability of high-quality evidence, in our opinion
asymptomatic dialysis patients could undergo dipyridamole-
MPS, followed by coronary angiography in case of an
abnormal scan. This combined physiological and anatomical
evaluation of the coronary circulation allows us to determine
which coronary stenosis is clinically relevant and therefore
should be revascularized.
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DOES SCREENING MAKE SENSE?
Although the high burden of coronary artery disease (CAD)
in the dialysis population is universally recognized, routine
screening has not yet been implemented in clinical practice.
As for any other disease in any other population, the
expected benefits of a screening program should be balanced
against the costs and side effects involved. Screening can
only be defended when there is a high prevalence of
asymptomatic disease in the population that is examined
and if intervention during the asymptomatic stage improves
outcome.
Prevalence of asymptomatic CAD in hemodialysis patients
In 1984, Rostand et al.1 found that only 10% of asympto-
matic dialysis patients had significant CAD (defined as a
narrowing of the coronary artery lumen of more than 50%),
a prevalence not so different from that reported in the general
population at that time. The mean age of the population
studied was 48 years and none had diabetes. More than a
decade later, Joki et al.2 reported a prevalence of CAD
(stenosis of at least 75%) in 54% of asymptomatic patients,
examined within 1 month of initiation of hemodialysis.
Ohtake et al.3 studied 30 asymptomatic patients, with a mean
age of 63 years and a prevalence of diabetes of 40%, and
without a history of cardiac disease at the initiation
of dialysis. Coronary angiography demonstrated the presence
of significant lesions (stenosis of at least 50%) in 53% of
the population and in 83% of those with diabetes. The
distribution of one-vessel, two-vessel, and three-vessel
disease was 62.5%, 25%, and 12.5%, respectively. Charytan
et al.4 performed coronary angiography in 67 asymptomatic
hemodialysis patients, with a mean age of 57 years, a
prevalence of diabetes of 48%, and a dialysis vintage of
3.4 years. Significant CAD (stenosis of at least 50%) was
found in 42% of the patients, 75% of whom had multivessel
involvement.
Conversely, the majority of dialysis patients with angio-
graphically documented CAD are asymptomatic. Braun
et al.5 reported that 75% of diabetic hemodialysis patients
with confirmed coronary artery stenoses had no symptoms.
In two other studies, 74% and 67% of dialysis patients with
CAD were asymptomatic at the time of angiography.6,7
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In conclusion, the prevalence of asymptomatic CAD in
hemodialysis patients appears to rise commensurately
with the increasing age and prevalence of diabetes in the
hemodialysis population. The absence of symptoms is
generally attributed to diabetic and uremic autonomic
neuropathy, although it is especially driven by reduced
exercise capacity in the dialysis population. Unlike in the
general population, the lack of angina does not imply that a
hemodynamically significant stenosis is absent. ‘Asympto-
matic’ CAD in dialysis patients should therefore be
interpreted very differently from asymptomatic CAD in the
population without renal disease.
The effect of intervention on outcome in the dialysis
population
Whether intervention, either by percutaneous coronary
intervention (PCI) or by coronary artery bypass grafting
(CAGB), improves outcome in hemodialysis patients with
proven CAD, either with or without symptoms, remains at
present unresolved. The large randomized controlled trials
(RCTs) that have documented the benefits of revasculariza-
tion in the general population have generally excluded
patients with renal disease, particularly those on maintenance
dialysis. Conclusions from these trials therefore cannot
be extrapolated to the dialysis population, especially as the
complication rate of revascularization procedures is signifi-
cantly increased in these patients. If no benefit is derived,
revascularization could even be harmful to dialysis patients.
Observational data suggest that revascularization may
provide a survival benefit as compared with conservative
treatment alone. Of 640 end-stage renal disease patients
experiencing an acute myocardial infarction, only 7% were
referred for PCI and 5% underwent CABG.8 One-year
survival rates were 45%, 54%, and 69% in those treated
with medical therapy alone, PCI, and CABG, respectively.8
A large prospective data collection investigated the outcome
by treatment (CAGB, PCI, or no revascularization) in
patients who fell under three categories of kidney function:
dialysis-dependent kidney disease, non-dialysis-dependent
kidney disease, and a reference group with a serum creatinine
below 2.3mg/dl.9 CABG was associated with a survival
advantage for all categories of kidney function, and PCI
conferred a lower risk of death in dialysis and reference
patients, as compared with no revascularization. However,
the majority of dialysis and non-dialysis kidney disease
patients did not undergo revascularization, even though
they were found to have more severe CAD at coronary
angiography than did the reference group. These findings
reveal the intrinsic problem with all observational studies in
the population with renal disease: physicians are reluctant to
perform invasive procedures in the most severely ill patients.
Although adjustments for clinical risk factors are generally
made in observational studies, there is always unmeasured
comorbidity that cannot be accounted for. Nonrandomized
trials are therefore unavoidably biased at the disadvantage of
the conservative approach.
At present, only one RCT has compared invasive and
conservative treatment in dialysis patients with CAD. Manske
et al.10 randomized 26 asymptomatic dialysis patients with
diabetes type 1 and documented CAD either to revascular-
ization with CABG or PCI or to medical treatment with a
calcium channel blocker and aspirin. The conservatively
managed patients had significantly more nonfatal and fatal
myocardial infarctions than did the revascularized group.
The results were remarkable, but should be interpreted with
caution, as the conservative treatment given at the time
differs from what is currently considered to be the ‘optimal
medical therapy’.
Yasuda et al.11 performed coronary angiography in
259 hemodialysis patients, 122 of whom had no significant
lesions. The other patients were informed about the benefits
and risks of PCI and made the decision whether to proceed
with it (88 patients) or not (49 patients) jointly with the
physicians.11 Both all-cause and cardiac 5-year survival
rates were strikingly higher in the PCI group than in the
medication-only group. Although this was not an RCT,
the survival benefit was so large that it was unlikely the sole
consequence of referral bias.
NONINVASIVE SCREENING FOR CAD IN HEMODIALYSIS
PATIENTS
Different noninvasive screening techniques are available, but
unfortunately all have limitations in the dialysis population
(Table 1).
Measurement of cardiac troponins
Cardiac troponin (cTn) T and I are sensitive markers of
damage to the myocardium. Serum cTn levels are commonly
increased in hemodialysis patients without acute coronary
syndrome. This has been attributed to left ventricular
Table 1 | Limitations of the available noninvasive screening
techniques in ESRD patients
Noninvasive screening test Limitations in ESRD patients
Cardiac troponin
measurement
Prognostic significance of high-sensitivity
assays unknown
Exercise tolerance test Poor exercise performance
High proportion of baseline ECG
abnormalities
Myocardial perfusion
scintigraphy
Low sensitivity reported
Dobutamine stress
echocardiography
Operator dependent
Adequate acoustic windows not possible
in up to 20%
Quantification of coronary
calcium score
No correlation calcification score—stenosis
in ESRD
CT coronary angiography Contrast exposure
Low specificity due to high coronary
calcium burden
Cardiac PET No data in patients with ESRD
Not widely available
Cardiac MRI Inability to use gadolinium
Technical problems
Abbreviations: CT, computed tomography; ESRD, end-stage renal disease;
MRI, magnetic resonance imaging; PET, positron emission tomography.
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hypertrophy, silent myocardial ischemia, or heart failure.12
A large body of evidence supports the prognostic value
of elevated cTn in asymptomatic dialysis patients.12 A meta-
analysis of 28 studies covering 3931 patients revealed that
cTnT measured at a single time point correlated with all-
cause and cardiac mortality, whereas the data for cTnI were
less straightforward, mainly because of the lack of assay
standardization.13 The presence of elevated levels of cTnT
may thus identify a subgroup of patients who deserve
further cardiac evaluation and more aggressive treatment.
Serial measurement of cTnT may improve the predictive
value of the test.14 The newest generation of cTn assays has
reduced the limit of detection by 10- to 100-fold and is being
adopted by a growing number of medical institutions. Using
these high-sensitivity assays, elevated cTnI has been reported
in 41% of asymptomatic hemodialysis patients,15 whereas
cTnT was increased in 100% of patients.16 The prognostic
significance of these findings is at present unstudied.
Exercise tolerance test
In the general population, the sensitivity and specificity of
exercise testing for obstructive CAD are 68% and 77%,
respectively,17 assuming that an adequate exercise level (85%
of age-adjusted predicted maximal heart rate) is attained.
Dialysis patients are, however, notorious for their reduced
exercise capacity, owing to deconditioning and to vascular,
neurological, or musculoskeletal comorbidities. Moreover,
many of these patients have a blunted chronotropic response
as a result of autonomic dysfunction. Several studies have
documented that only 7–53% of dialysis patients achieve the
target heart rate.18–22 The increasing age and comorbidity of
the dialysis population can only reduce the likelihood of
obtaining a diagnostic test. In addition, the high prevalence
of baseline electrocardigram abnormalities in dialysis patients
hampers the interpretation of an exercise test. Exercise
tolerance testing is therefore not generally recommended as a
screening tool in the dialysis population.
Myocardial perfusion scintigraphy (MPS)
Myocardial blood flow can be measured by injecting a
radioactive tracer that distributes through the myocardium
in proportion with blood flow. The tracers used are
99mTechnetium-methoxyisobutylisonitrile, 99mTechnetium-
tetrofosmin, and 201Thallium. The distribution of these
tracers is measured with single-photon emission computed
tomography. The test is always conducted both at rest and
after a cardiac stress, the latter to reveal flow heterogeneity
induced by a hemodynamically significant coronary stenosis.
A perfusion defect that is only present during stress and not
at rest is indicative of ischemia (¼ reversible defect). Areas of
myocardial infarction with scarring will show as perfusion
defects both at stress and at rest studies (¼ irreversible
defect).
Currently used cardiac stressors are exercise, dipyridamole
(Persantine, Boehringer Ingelheim, Brussels, Belgium),
adenosine, and dobutamine. In the dialysis population,
exercise-MPS has the same limitations as exercise-electro-
cardiogram, related to the inadequate exercise performance
and chronotropic incompetence of the patients. The most
frequently used cardiac stressor is dipyridamole.
It increases levels of adenosine, which induces regional
hyperemia commensurate with the flow reserve of each
coronary artery. Dobutamine is a b1-adrenergic receptor
agonist that increases myocardial oxygen consumption
through its combined inotropic and chronotropic effect,
and thus mainly indirectly causes coronary vasodilation.
A prospective head-to-head comparison of dipyridamole and
dobutamine as cardiac stressors in 121 hemodialysis patients
revealed that dobutamine stress induced more, larger and
more intense reversible perfusion defects than did dipyr-
idamole stress, especially in the anteroseptal segments.23
However, a perfusion defect during dipyridamole was more
specific in demonstrating a coronary stenosis and was a better
predictor of a future cardiac event than was a perfusion defect
during dobutamine.23 The chronotropic action of dobuta-
mine may induce alterations of wall motion leading to
spurious perfusion defects, similar to the artifacts seen with
left bundle branch block. These data were confirmed by a
head-to-head comparison of dobutamine stress echocardio-
graphy, dobutamine MPS, and adenosine MPS, showing that
dobutamine stress echocardiography (DSE) and dobutamine
MPS did not provide incremental prognostic information
when added to clinical data and ejection fraction, in contrast
to adenosine MPS.24 Therefore, dipyridamole is the cardiac
stressor of choice in the hemodialysis population.
Several studies have evaluated the diagnostic ability
of dipyridamole MPS by using coronary angiography as
‘the gold standard’.16,23,25–29 Widely varying sensitivities and
specificities have been reported (Table 2). A factor that may
account for low sensitivity is the presence of balanced
ischemia when flow is equally diminished in all myocardial
areas. Balanced ischemia does not show on MPS, as the
technique measures relative, as opposed to absolute, perfu-
sion. The low sensitivities have also been attributed to an
impaired vasodilatory response to adenosine in the dialysis
population. It has been contended that dialysis patients have
abnormally high resting levels of adenosine, although the
only evidence to support this is the notion of decreased
lymphocyte adenosine deaminase activity in patients with
renal failure.30 However, a blunted vasodilation to adenosine
has been reported in diabetes and left ventricular hyper-
trophy, both of which are common in dialysis patients.
Another potential explanation for the apparently low
diagnostic ability of MPS is that coronary angiography may
not be the best standard to assess the performance of MPS.
MPS is a functional test that measures coronary blood flow,
whereas coronary angiography provides only anatomical
information. Multiple factors may intervene between a
stenosis of a coronary artery and diminished blood flow,
including the functional severity of the stenosis, the presence
of collateral circulation, and the status of the distal
vascular bed and the microcirculation. If extensive collateral
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circulation has developed, a coronary stenosis may not result
in decreased myocardial blood flow. Conversely, extensive
microvascular disease may cause decreased myocardial
blood flow in the absence of a flow-limiting stenosis of the
epicardial coronary arteries. The ability to predict CAD-
related events may therefore be a more relevant criterion to
judge MPS rather than the comparison with coronary
angiography.
Several studies have evaluated the value of MPS to predict
cardiac events in patients with end-stage renal dis-
ease.14,27–29,31–46 The large majority found that abnormal
MPS predicted cardiac events in univariate analysis
(Figure 1a and b). Several studies have corroborated that
the predictive power of MPS remains after correction for
clinical variables in multivariate analysis.29,40,42,43 In a meta-
analysis of 12 studies using dobutamine stress echocardio-
graphy or MPS with either pharmacological or exercise stress,
the presence of a reversible defect was associated with a
significantly increased risk of myocardial infarction and
cardiac death.47
In a prospective study of 150 patients being evaluated for
renal transplantation, the prognostic ability of MPS and
coronary angiography was compared.48 In a multivariate
model, only an abnormal MPS result and diabetes were
independent predictors of death, whereas the number of
narrowed coronary arteries was not. Thus, MPS had better
prognostic power than coronary angiography in this study.
Similarly, in a study of 47 patients being assessed for kidney
transplantation, the accuracy for predicting all-cause death
was higher for MPS than for coronary angiography.49 In
contrast, the presence of a coronary stenosis better predicted
future cardiac events than did an abnormal MPS or
dobutamine stress echocardiography in another prospective
study of 126 renal transplant candidates.41 Angiographic
evidence of CAD was the only independent predictor of
major cardiac events in a cohort of 280 diabetic transplant
candidates who had also undergone MPS.50 Observational
trials in this matter are inevitably confounded by the
revascularization procedures that may follow coronary
angiography, making it difficult to dissociate the effect of
the therapeutic act from the impact of either the absence or
presence of CAD.
Dobutamine stress echocardiography
Dobutamine stress echocardiography is often recommended
as a valid screening test in the end-stage renal disease
Table 2 | Studies examining the diagnostic ability of dipyridamole myocardial perfusion scintigraphy, using coronary
angiography as the gold standard
Author n Stress Criterium % Sensitivity Specificity Accuracy
Orie et al.25 20 Dipyridamole 50 73 100 85
Boudreau et al.26 80 Dipyridamole 70 86 79 83
Marwick et al.27 45 Dipyridamole 50 37 73 58
70 29 68 56
Vandenberg et al.28 47 Dipyridamole/adenosine 50 53 73 63
70 62 76 71
Dahan et al.29 76 Dipyridamole+exercise 70 92 89 90
Schmidt et al.21 55 Dipyridamole 70 80 37 59
De Vriese et al.23 62 Dipyridamole 70 62 54 58
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Figure 1 |Hazard ratios for composite cardiac end points in patients with end-stage kidney disease reported in studies on
myocardial perfusion scintigraphy (MPS). End points variably included cardiac death, unstable angina, myocardial infarction, congestive
heart failure or pulmonary edema, arrhythmia, and need for revascularization. The stressors are: E¼ exercise, Di¼dipyridamole,
Do¼dobutamine, A¼ adenosine, ATP¼ adenosine triphosphate; some studies have used different stressors in different patients; Dahan
et al.29 have used a combination of E and Di in every patient. Studies that reported different data sets may appear twice (zhemodialysis
patients; zzrenal transplant patients; *patients followed up for cardiac death; **patients followed up for cardiac death or nonfatal cardiac
events). Hazard ratios are given for results demonstrating ischemia versus those without evidence for ischemia (a) and for results
demonstrating either ischemia or scar vs. those without evidence for ischemia or scar (b). The 95% confidence intervals of the hazard ratio
are presented on a semilogarithmic scale.
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population.51 Besides demonstrating CAD, it may reveal the
location and extent of the ischemia and scar. In addition,
DSE can provide information on valvular disease, left
ventricular hypertrophy, and volume status.
The technique is based on the recognition of wall motion
disturbances: if present at rest, they signify scar; if appearing or
worsening at stress, they signify ischemia. As with MPS,
stressors may be vasodilatory agents29,52 or, far more frequently,
dobutamine. Many dialysis patients do not achieve target heart
rate,51,53–56 thereby decreasing the sensitivity of the test,
although failure to attain maximal stress may itself be a risk
factor for subsequent cardiac events.57 In addition, a substantial
number of patients show hypertensive responses to the infusion
of dobutamine,41 which may be predicted by the presence of
hypertension at baseline.52 Other studies have found no higher
incidence of dose-limiting side effects in chronic renal failure
patients compared with the general population.54 Finally, the
interpretation of the test is operator dependent and requires
extensive experience. From a technical point of view, adequate
acoustic windows may not be obtained in up to 20% of the
tests. As many dialysis patients have left ventricular hyper-
trophy, the small intracavitary volume at peak dobutamine
stress may obscure the detection of wall motion abnormal-
ities.51
The diagnostic accuracy of DSE for the detection of
significant epicardial coronary stenoses is variable. Much
of what has been said of MPS, being a functional test as
opposed to the anatomical evaluation of the coronary arteries
by coronary angiography, holds for DSE as well. It is
noteworthy that the only study that directly compared DSE
and dipyridamole MPS in a cohort of high-risk transplant
candidates concluded that both were similarly associated with
inadequate sensitivities, although the negative predictive
values were fair.41
Several studies examined the prognostic power of DSE
in the end-stage renal disease population.17,41,51,52,54,55,58,59
The ability of DSE to predict cardiac events in a
univariate analysis has generally been reported as excellent
(Figure 2a and b). Similar to MPS, most studies have
documented that the predictive powers of DSE remain
after correction for clinical variables in multivariate
analysis.17,52,54,55,58
Measurement of coronary calcium score
Electron-beam computed tomography and multislice com-
puted tomography are both sensitive tools to detect and
quantify deposits of calcium in soft tissues, in general, and
in coronary arteries, in particular.60 Although these two
technologies provide the same type of information, they
operate on the basis of different imaging platforms. Electron-
beam computed tomography uses a rotating fan of X-rays
produced by the impact of a beam of electrons against a
tungsten ring and obtains 3mm contiguous slices. Multislice
computed tomography uses a paired X-ray source detector
revolving around the patient and obtains 2–64 simultaneous
sections with a thickness varying from 1.5 to 0.6mm, thus
providing a higher spatial resolution than does electron-
beam computed tomography. Electron-beam computed
tomography requires specific equipment that is not available
outside research settings, which is a major obstacle to its
routine application.
Computed tomography imaging allows the precise
quantification of coronary calcifications by means of the
two-dimensional Agatston score or the three-dimensional
volume score.60 Coronary calcium scores predict mortality in
dialysis patients.61,62 However, unlike in the general popula-
tion, coronary calcium scores in dialysis patients do not
appear to correlate well with angiographic findings.63 A low
or negative calcium score had a high negative predictive
value, but once substantial calcifications were present
they did not predict luminal narrowing.63 Measurement
of coronary calcifications is therefore not the best tool to
identify a coronary stenosis and predict the future need for a
coronary intervention in dialysis patients.
Computed tomography coronary angiography
Computed tomography coronary angiography is used
in the general population to evaluate patients with a
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Figure 2 |Hazard ratios for composite cardiac end points in patients with end-stage kidney disease reported in studies on
echocardiography. The stressors used in the studies are specified (Di¼dipyridamole, Do¼ dobutamine). Hazard ratios are given for results
demonstrating ischemia versus those without evidence for ischemia (a) and for results demonstrating either ischemia or scar versus those
without evidence for ischemia or scar (b). The 95% confidence intervals of the hazard ratio are presented on a semilogarithmic scale.
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low-to-intermediate pretest probability of CAD in order to
avoid an invasive procedure. The technique has not been
studied extensively in the dialysis population.64 Exposure to
iodinated contrast has been reduced to 70–80ml with newer
equipment and shorter acquisition times, but may still affect
residual renal function. In addition, advanced coronary
calcifications may hamper the interpretation, because they
generate an intense signal that may be difficult to distinguish
from the contrast-enhanced vessel lumen.
Cardiac positron emission tomography
This modality of nuclear imaging uses a positron emission
tomography camera and short-lived positron emitters such as
82Rubidium and 13N-ammonia as flow tracers. Similar to the
flow tracers used with traditional MPS, these positron-
emitting tracers can be injected intravenously during stress.
Unlike traditional MPS, positron emission tomography
allows for absolute quantification of myocardial blood flow.65
Cardiac positron emission tomography detects angiographic
stenoses with considerable accuracy and adds risk prediction
to clinical risk models. However, the technique is not widely
available and has not been validated in patients on renal
replacement therapy.
Cardiac magnetic resonance imaging
Because of the association of gadolinium-based contrast
with nephrogenic systemic fibrosis, the use of these agents for
screening purposes is no longer an option in the hemodialysis
population. Flow-related enhancement without the use of
gadolinium can also be used for the visualization of coronary
arteries. However, accurate three-dimensional data acquisi-
tion requires respiratory gating and cardiac triggering and
takes a long time (12–15min in some patients), often
resulting in movement of artifacts. Further technical adjust-
ments will therefore be required before the technique can be
validated as a screening tool for CAD.
CORONARY ANGIOGRAPHY
Coronary angiography remains ‘the gold standard’ for the
diagnosis of CAD. Coronary angiography has been criticized
as a screening tool because of its high costs, invasive nature,
and the presumed untoward effects on residual renal
function. Roughly one-third of patients with glomerular
filtration rateo30ml/min develop contrast-induced nephro-
pathy after PCI, even when prehydration prophylaxis is
adequately applied.66 Patients who develop acute kidney
injury following coronary angiography are at increased risk
for progressive long-term loss of kidney function.67 In spite
of this, the direct consequence of coronary angiography on
residual renal function in dialysis patients has been evaluated
in only a few studies, none of which were randomized.68,69
Rather contraintuitively, no acceleration of the decline in
residual renal function was reported.
The rational use of coronary angiography as a screening
test implies that the finding of ‘significant’ stenosis is
followed by an intervention. In the general population,
however, coronary intervention does not improve survival
in asymptomatic patients.70,71 In non-renal patients, most
myocardial infarctions result from erosion or rupture of
unstable atherosclerotic plaques in coronary arteries that
were not necessarily significantly narrowed (referred as Type
1 myocardial infarction).72 In dialysis patients, however,
sudden death and congestive heart failure are more common
causes of cardiovascular death than is Type 1 acute
myocardial infarction. A sizeable number of cardiac deaths
in the dialysis population may be caused by Type 2 (ischemia
due to either increased oxygen demand or decreased supply)
and Type 3 (sudden cardiac death with signs or symptoms
suggestive of myocardial ischemia, but occurring before
cardiac biomarkers can be obtained) myocardial infarctions.
In addition, it may well be that the asymptomatic stenoses
in dialysis patients are more severe and hemodynamically
significant than those in the general population, as
autonomic neuropathy and the sedentary lifestyle of these
patients may prevent these stenoses from becoming clinically
apparent. A severe stenosis has a greater probability of
progressing to occlusion and to cause either a myocardial
infarction or ischemic ventricular dysfunction. Taken
together, ‘asymptomatic’ CAD may have very different
pathophysiological causes and consequences in the dialysis
than in the general population, and therefore should be
addressed differently.
The importance of combined physiological and anatomi-
cal rather than solely anatomical assessment of the coronary
circulation was demonstrated recently in 1005 patients
with multivessel involvement.73 The FAME (Fractional Flow
Reserve versus Angiography for Guiding PCI in Patients with
Multivessel Coronary Artery Disease) trial studied the
additive value of a fractional flow reserve (FFR) measurement
in the decision whether or not to revascularize a coronary
stenosis. FFR is calculated as the ratio of the pressure distal to
the coronary stenosis and the aortic pressure at maximal
hyperemia induced by adenosine, and it is an index of the
physiological significance of the stenosis. FFR-guided PCI was
associated with a better outcome, a lower complication rate,
and lower costs compared with PCI directed by angiogra-
phical criteria alone. Although the FAME trial was conducted
in the general population,73 it may help to resolve the
dilemma of how to approach a coronary stenosis in an
asymptomatic dialysis patient. Ischemia-producing lesions,
which can be identified by an abnormal FFR or by a reversible
perfusion defect in the relevant area, should undergo
revascularization. Lesions that do not induce ischemia can
probably be safely managed conservatively. A potential but
yet unstudied limitation of FFR measurements in the dialysis
population is a possible impaired vasodilatory response
to adenosine.
WHO DESERVES TO BE SCREENED?
Although no studies have unequivocally demonstrated that
candidates for renal transplantation benefit from screening
for CAD,74 it remains a pillar of the pretransplant evaluation
148 Kidney International (2012) 81, 143–151
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process and is reiterated in all relevant guidelines.75–78
It should be noted that these guidelines are at odds with
those of the American College of Cardiology/American Heart
Association, which do not recommend screening asympto-
matic patients before surgery provided that their functional
status allows them to perform four or more metabolic
equivalent tasks.79
In addition to the patients being evaluated for renal
transplantation, the K-DOQI (Kidney Disease Outcomes
Quality Initiative) guidelines advocate screening for CAD in
patients with a history of revascularization, a significant
reduction in left ventricular function, and a change in clinical
status suggestive of a cardiac problem. Finally, they recom-
mend screening in selected high-risk patients at the discretion
of the treating physician. In view of the large proportion
of asymptomatic disease in dialysis patients, which is only
partially predicted by clinical risk factors, it appears non-
sequitur to recommend screening in these selected categories
and not in the dialysis population as a whole.
There are only few data on the optimal time to repeat
screening in patients who have tested negatively at the initial
evaluation. Out of 191, 51 chronic renal failure patients with
a normal DSE had a subsequent cardiac event rate of 4%
within 2 years, but this increased to 10% at 40 months.54
Similarly, in a study on 485 patients with chronic kidney
disease, 12% of 203 patients with a normal DSE died in the
first year after the test, whereas the mortality rate increased to
30% at 3 years.56 Of 100 hemodialysis patients with a normal
coronary angiography and/or MPS, 5 developed a major
adverse cardiac event during the second year following the
test.80 A normal MPS (normal global perfusion and left
ventricular ejection fraction 445%) was associated with a
2-year cardiac event rate of 15%.23 These data should be
compared with cardiac event rates below 1% per year
following a normal MPS in the general population.81
Retesting of patients with normal studies every 2 years thus
seems reasonable.
CONCLUSION
Asymptomatic CAD is very common in the dialysis
population on account of the increasing age and prevalence
of diabetes. However, the absence of symptoms cannot
be considered reassuring, because it is the consequence of
autonomic neuropathy and low exercise tolerance, rather
than of hemodynamically nonsignificant disease. The con-
tinuous presence of silent ischemia may be responsible for the
development of heart failure, arrhythmias, and sudden death
in dialysis patients. The approach to asymptomatic CAD in
dialysis patients thus cannot be extrapolated from studies
conducted in the general population.
No high-quality studies examined whether revasculariza-
tion improves the outcome of dialysis patients with CAD.
However, the available observational data, prospective
studies, and one small RCT documented a survival advantage
for patients treated with PCI or CABG compared with those
managed with medication only.
Patients on dialysis may not tolerate aggressive medical
therapy for CAD because of the hemodynamic effects of
beta-blockers, nitrates, and calcium channel blockers during
dialysis, hampering the achievement of target dry weight and
thus abrogating the potential benefit of the drug. What
constitutes an optimal medical therapy for CAD in the
general population may therefore not be applicable to dialysis
patients.82,83
Historically, revascularization procedures have been asso-
ciated with high complication rates in the dialysis popula-
tion. As a consequence, dialysis patients often have been
denied invasive therapies. However, recent sophistications
may have decreased the adverse effects of these techniques
and may be tipping the balance in favor of invasive treatment.
Taken together, all these issues reinforce the need for
a large RCT that examines the incremental benefit of
revascularization in addition to medical therapy in asympto-
matic dialysis patients with CAD. Such a trial should be
conducted under the aegis of National and/or International
Societies and independently of the industry. For CAD
screening in the context of the pretransplant evaluation
process, power calculations have been made on the basis of
preliminary studies.74,84 Assuming a 25% reduction in
cardiac events with revascularization and taking into account
a recruitment and follow-up period of 2.5 years, one needs to
randomize more than 700 patients with potentially remedi-
able CAD in order to obtain a sufficiently powered trial.74
To include this number of patients, more than 8000 potential
renal transplant recipients would need to be evaluated.74
Taking a somewhat different approach, standard screening
with prophylactic revascularization was compared with
screening of only high-risk patients.84 To detect a 20%
decrease in major adverse cardiovascular events, about 4000
transplant candidates would need to be enrolled.84
Pending the results of a large RCT, in our opinion all
incident dialysis patients could be screened with MPS,
followed by a coronary angiography in patients with a
positive test and revascularization of only those stenoses that
cause ischemia. In patients with a negative test, MPS may be
repeated every 2 years because of the potentially rapid
progression of CAD. As absence of evidence does not indicate
evidence of absence, we should not be discouraged to act
consistently with clinical intuition while awaiting the results
of conclusive studies, and refer the conservative approach
to the realm of therapeutic nihilism.
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